BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 94 filers reported holding BIOXCEL THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.86 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,173,571 | -69.5% | 463,862 | -19.6% | 0.00% | – |
| Q2 2023 | $3,844,751 | +3.5% | 577,290 | +190.0% | 0.00% | – |
| Q1 2023 | $3,714,851 | +88.9% | 199,081 | +117.5% | 0.00% | – |
| Q4 2022 | $1,966,064 | +15.5% | 91,530 | -36.5% | 0.00% | – |
| Q3 2022 | $1,702,000 | -29.7% | 144,050 | -21.5% | 0.00% | – |
| Q2 2022 | $2,421,000 | -52.2% | 183,396 | -24.3% | 0.00% | – |
| Q1 2022 | $5,068,000 | -55.5% | 242,397 | -56.7% | 0.00% | – |
| Q4 2021 | $11,378,000 | -24.9% | 559,646 | +12.2% | 0.00% | -100.0% |
| Q3 2021 | $15,142,000 | +10.7% | 498,924 | +6.0% | 0.00% | +50.0% |
| Q2 2021 | $13,681,000 | +6.2% | 470,796 | +57.8% | 0.00% | +100.0% |
| Q1 2021 | $12,878,000 | -70.5% | 298,386 | -68.4% | 0.00% | -66.7% |
| Q4 2020 | $43,644,000 | +160.5% | 944,664 | +144.5% | 0.00% | 0.0% |
| Q3 2020 | $16,753,000 | -12.9% | 386,350 | +6.5% | 0.00% | -40.0% |
| Q2 2020 | $19,236,000 | +597.5% | 362,888 | +194.1% | 0.01% | +400.0% |
| Q1 2020 | $2,758,000 | – | 123,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 430,000 | $19,866,000 | 1.70% |
| APIS CAPITAL ADVISORS, LLC | 20,000 | $924,000 | 0.89% |
| Avidity Partners Management LP | 547,000 | $25,271,000 | 0.82% |
| Knoll Capital Management, LLC | 20,000 | $924,000 | 0.63% |
| Artemis Investment Management LLP | 1,013,448 | $46,839,000 | 0.49% |
| AlphaCentric Advisors LLC | 25,000 | $1,155,000 | 0.48% |
| First Light Asset Management, LLC | 94,202 | $4,352,000 | 0.32% |
| Ikarian Capital, LLC | 150,000 | $6,930,000 | 0.31% |
| Longitude (Cayman) Ltd. | 8,000 | $370,000 | 0.18% |
| AllSquare Wealth Management LLC | 5,490 | $254,000 | 0.17% |